Category: 50998-17-9

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

50998-17-9, To a stirred solution of compound 1A (0.2 g, 0.79 mmol) and 2-methoxy-6-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine lB (0. 24 g, 1.02 mmol) in 1,4-dioxane (10 mL)/H20 (2 mL) was added K3P04 (0.5 g, 2.36 mmol). The reaction mixture was degassed for 3 mm. and then to it was added the PdC12(dppf)-CH2C12 adduct (0.032 g, 0.03 9 mmol), and the resultant mixture was heated at 100 C for 12 h. The reaction mixture was then filtered through a Celite pad, the filter cake washed with ethyl acetate and the combined filtrate evaporated under reduced pressure to give the cmde compound, which was purified by preparative HPLC (condition N) to yield 6-(6?-methoxy-[2,2?-bipyridinj -3-yl)imidazo [1,2- ajpyridine-3-carbonitrile 17 (0.2 mg, 0.054 mmol, 68.5 % yield). Compound 20B was synthesized by reacting 20A and 2-chloro-3-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)pyridine (reference: WO 2015157093 Al, WO 2015044172 Al and WO 2014055955 Al) employing the experimental procedure described in Scheme-5 (Method E). The cmde product was purified by silica gel chromatography (40 g RediSep column, eluting with 50 % ethyl acetate in petroleum ether) to yield compound 20B (2.32 g, 9.610 . +mmol, 67.0 /o yield) as alight yellow solid. LCMS: m/z = 242.0 [M+Hj ; ret. time 1.66 mm; condition C.

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; RIGEL PHARMACEUTICALS, INC.; BRISTOL-MYERS SQUIBB COMPANY; DING, Pingyu; GELMAN, Marina; KINSELLA, Todd; SINGH, Rajinder; BHAMIDIPATI, Somasekhar; VELAPARTHI, Upender; BORZILLERI, Robert, M.; RAHAMAN, Hasibur; WARRIER, Jayakumar, Sankara; (232 pag.)WO2016/133838; (2016); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

50998-17-9, To a flask including 1 eq. of triphenylen-2-ylboronic acid and 1.2 eq. of 6-bromoquinoxaline, 0.03 eq. of Pd(dba)3, 0.06 eq. of (t-Bu)3P, and toluene (1 M) were added and refluxed with stirring for about 12 hours. Then, the reaction product was cooled to ambient temperature, extracted with methylene chloride and washed with distilled water. The product thus obtained was dried with MgSO4 and distilled under a reduced pressure, and the residue was separated by column chromatography to produce Compound B-1 (Yield 80.4%). The compound thus produced was identified using a high resolution mass spectrometer and 1H NMR. The mass of the synthesized compound thus identified was 355. [HRMS for C26H16N2 [M]+: calcd: 356.43, found: 355, Elemental Analysis for C26H16N2 calcd: C, 87.62; H, 4.52; N, 7.86].

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; SAMSUNG DISPLAY CO., LTD.; JEONG, Hyein; LEE, Jungsub; (58 pag.)US2017/162796; (2017); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9

To a solution of 11g (30 mg, 113 mumol), 6-bromoquinoxaline (36 mg, 172 mol), Bu4NOAc (66.2 mg, 220 mol) and Pd(OAc)2 (3.7 mg, 16.5 mol) in NMP (0.5 mL ). The reaction mixture was stirred for 32 h at 100 oC and cooled to room temperature. The mixture was concentrated under reduced pressure. Diluted with water and extracted with EtOAc (3 ¡Á 5 mL). The EtOAc solution was washed with brine (5 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (1:1 hexane/EtOAc) to afford the compound 12g (6.1 mg, 14%) as a pale yellow solid. TLC: Rf 0.3 (1:1 hexane/EtOAc). mp: 133136 oC. 1H-NMR (400 MHz, CDCl3) delta 8.83 (d, 1H, J = 2.0 Hz), 8.80 (d, 1H, J = 2.0 Hz), 7.99 (d, 1H, J = 8.8 Hz), 7.92 (d, 1H, J = 2.0 Hz), 7.75 (t, 1H, J = 8.0 Hz), 7.65-7.62 (m, 3H), 7.33 (m, 1H), 7.17 (d, 1H, J = 8.0 Hz), 7.03 (td, 1H, J = 8.0 Hz, J = 1.2 Hz), 6.78 (d, 1H, J = 8.0 Hz), 3.27 (s, 3H), 2.27 (s, 3H). 13C-NMR (100 MHz, CDCl3) delta 158.5, 156.7, 149.4, 145.6, 145.5, 144.2, 142.7, 142.6, 139.2, 134.1, 132.1, 131.9, 131.8, 130.5, 130.1, 128.6, 123.9, 121.1, 119,6, 116.1, 111.2, 54.8, 23.9. HRMS (ESI) calcd. for C23H19N6O (M+H): 395.1615; found 395.1620.

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Li, Fei; Park, Yunjeong; Hah, Jung-Mi; Ryu, Jae-Sang; Bioorganic and Medicinal Chemistry Letters; vol. 23; 4; (2013); p. 1083 – 1086;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

To a solution of 11b (103.8 mg, 451 mumol), 6-bromoquinoxaline (142 mg, 679 mumol), Bu4NOAc (271 mg, 0.9 mmol) and Pd(OAc)2 (15.2 mg, 67.5 mol) in NMP (0.9 mL). The reaction mixture was stirred for 22 h at 100 oC and cooled to room temperature. The mixture was concentrated under reduced pressure, diluted with water, and extracted with EtOAc (3 ¡Á 5 mL). The EtOAc solution was washed with brine (5 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (1:1 hexane/EtOAc) to afford the compound 12b (91 mg, 56%) as a pale yellow solid. TLC: Rf 0.37 (1:1 hexane/EtOAc). mp: 96.0-98.0 oC. 1H-NMR (400 MHz, CDCl3) delta 8.90 (AB quartet, 2H, J = 2.0 Hz), 8.09 (d, 1H, J = 8.8 Hz), 8.07 (d, 1H, J = 2.0 Hz) 7.72 (t, 1H, J = 8.0 Hz), 7.63 (dd, 1H, J = 8.8 Hz, J = 2.0 Hz), 7.60 (d, 1H, J = 8.0 Hz), 7.12(d, 1H, J = 8.0 Hz), 2.80 (m, 2H), 2.20 (s, 3H), 1.69-1.60 (m, 3H), 0.86 (d, 6H, J = 6.4 Hz). 13C-NMR (100 MHz, CDCl3) delta 158.2, 149.3, 147.8, 145.9, 145.8, 142.8, 142.7, 139.1, 132.6, 132.2, 131.0, 130.4, 129.2, 123.5, 115.2, 38.7, 27.8, 23.8, 23.1, 22.5. HRMS (ESI) calcd. for C21H23N6 (M+H): 359.1979; found 359.1983., 50998-17-9

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Article; Li, Fei; Park, Yunjeong; Hah, Jung-Mi; Ryu, Jae-Sang; Bioorganic and Medicinal Chemistry Letters; vol. 23; 4; (2013); p. 1083 – 1086;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9,50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 13A 1-Quinoxalin-6-yl-ethanone A solution of 6-bromo-quinoxaline (261 mg, 1.25 mmol), 1-ethoxyvinyltri-n-butyltin (0.47 mL, 1.4 mmol), palladium(II) acetate (16 mg) and tri-t-butylphosphonium tetrafluoroborate (41 mg) in anhydrous DMF (4 mL) under a nitrogen atmosphere was heated at 120 C. for 1 hr. The reaction mixture was cooled to ambient temperature and partitioned between ethyl acetate (25 mL) and H2O (10 mL). The organic extraction was washed with brine, dried (MgSO4), filtered, and concentrated. The concentrate was chromatographed on silica gel eluding with ethyl acetate:hexanes (1:1) to provide 110 mg of the title compound. 1H NMR (300 MHz, CDCl3) delta 2.79 (s, 3H), 8.18 (d, J=9 Hz, 1H), 8.36 (dd, J=9 Hz, J=3 Hz, 1H), 8.70 (d, J=3 Hz, 1H), 8.95 (s, 2H); MS (DCl/NH3) m/z 173 (M+H)+.

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; Altenbach, Robert J.; Black, Lawrence A.; Chang, Sou-Jen; Cowart, Marlon D.; Faghih, Ramin; Gfesser, Gregory A.; Ku, Yi-Yin; Liu, Huaqing; Lukin, Kirill A.; Nersesian, Diana L.; Pu, Yu-ming; Curtis, Michael P.; US2005/272736; (2005); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,50998-17-9

EXAMPLE 622,5-Dimethyl-5-[3-(quinoxalin-6-yl)phenyl1tetrahydrofuran-2-ol6-Bromoquinoxaline (3.14 g, 15 mmol) was dissolved in DME/water (9:1, 500 niL), and 3-acetylphenylboronic acid (2.5 g, 15 mmol), cesium carbonate (9.75 g, 30 mmol) and Pd(PPh3 )4 (870 mg, 0.75 mmol) were added. The mixture was heated to 1100C for 18 h. After cooling, the mixture was partitioned between EtOAc and water (100 mL each), and the organic phase concentrated in vacuo. The residue was triturated with diethyl ether (50 mL) to give l-[3-(quinoxalin-6-yl)phenyl]ethanone (3.8 g, >95%). LCMS (ES+) 249.2 (M+H)+, RT 3.04 minutes. A sample of this material (500 mg, 2 mmol) was dissolved in THF (4 mL), and cooled to O0C. But-l-en-4-ylmagnesium bromide (0.5M in THF, 4 mL, 2 mmol) was added and the mixture allowed to warm to room temperature. After stirring for 2 h, water (2 mL) was added. The organic phase was passed though a silica plug and concentrated in vacuo. The residue was dissolved in DCM (3 mL). 7V-Bromosuccinimide (146 mg, 0.9 mmol) was added and the mixture stirred at room temperature for 18 h. The mixture was partitioned between DCM (5 mL) and saturated sodium hydrogencarbonate solution (5 mL). The organic phase was passed through a silica plug and the filtrate concentrated in vacuo. The residue was dissolved in MeOH (3 mL). Sodium methoxide (200 mg) was added and the mixture was stirred at 600C for 3 days. The mixture was neutralized to pH 7.0 with IM hydrochloric acid and then concentrated in vacuo. The residue was purified by preparative HPLC to isolate the title compound (5 mg, 2:1 mixture of cis:trans isomers). deltaH (CDCl3) 8.89 (d, IH), 8.86 (d, IH), 8.32 (m, IH), 8.20 (m, IH), 8.08 (m, IH), 7.84 (m, IH), 7.62 (m, IH), 7.50 (m, 2H), 2.10-2.58 (m, 4H), 2.11 (s, 3H), 1.56-1.72 (m, 4H). LCMS (ES+) 321.3 (M+H)+, RT 2.93 minutes.

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; UCB PHARMA S.A.; BUeRLI, Roland; HAUGHAN, Alan, Findlay; MACK, Stephen, Robert; PERRY, Benjamin, Garfield; RAPHY, Gilles; SAVILLE-STONES, Elizabeth, Anne; WO2010/52448; (2010); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9

To a solution of 11e (70.0 mg, 296 mumol), 6-bromoquinoxaline (94.1 mg, 450 mumol), Bu4NOAc (181 mg, 600 mol) and Pd(OAc)2 (10.1 mg, 45.0 mol) in NMP (0.6 mL). The reaction mixture was stirred for 23 h at 100 oC and cooled to room temperature. The mixture was concentrated under reduced pressure. Diluted with water and extracted with EtOAc (3 ¡Á 5 mL). The EtOAc solution was washed with brine (5 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (1:1 hexane/EtOAc) to afford the compound 12d (15 mg, 14%) as a yellow solid. TLC: Rf 0.2 (1:1 hexane/EtOAc). mp: 208-210 oC. 1H-NMR (400 MHz, CDCl3) delta 8.89 (d, 1H, J = 1.6Hz), 8.85 (d, 1H, J = 1.6 Hz), 8.12 (d, 1H, J = 8.4 Hz), 8.07 (d, 1H, J = 1.6 Hz), 7.76 (dd, 1H, J = 8.4 Hz, J = 2.0 Hz), 7.73 (t, 1H, J = 7.6 Hz), 7.64 (d, 1H, J = 7.6 Hz), 7.59-7.57 (m, 2H), 7.30-7.27 (m, 3H), 7.12 (d, 1H, J = 7.6 Hz), 2.18 (s, 3H). 13C-NMR (100 MHz, CDCl3) delta 158.3, 149.1, 146.2, 145.9, 145.8, 143.0, 142.7, 139.1, 132.6, 132.4, 131.6, 131.0, 130.4, 129.5, 128.8, 128.4, 127.8, 123.7, 115.7, 23.8. HRMS (ESI) calcd. for C22H17N6 (M+H): 365.1509; found 365.1512.

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Article; Li, Fei; Park, Yunjeong; Hah, Jung-Mi; Ryu, Jae-Sang; Bioorganic and Medicinal Chemistry Letters; vol. 23; 4; (2013); p. 1083 – 1086;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

50998-17-9, INTERMEDIATE 13 -(Quinoxalin-6-yl)benzaldehydeA mixture of 6-bromoquinoxaline (210 mg, 1.01 mmol), 3-formylphenylboronic acid (301 mg, 2.01 mmol), 2M aqueous sodium carbonate solution (1.7 mL, 14.4 mmol) and Pd(PPh3)4 (35 mg, 0.03 mmol) in DME (3.5 mL) was heated to 1200C in a sealed tube, under microwave irradiation, for 20 minutes. After cooling, the organic phase was adsorbed onto silica and purified by column chromatography (SiO2, 10-100% EtOAc in heptane) to give the title compound (340 mg) as a beige solid. 6H (CDCl3) 10.15 (s, IH), 8.91 (d, IH), 8.89 (d, IH), 8.38 (d, IH), 8.26-8.31 (m, IH), 8.24 (d, IH), 8.10 (dd, IH), 8.02-8.07 (m, IH), 7.94-8.00 (dd, IH), 7.72 (t, IH). LCMS (ES+) 235 (M+H)+, RT 2.99 minutes.

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; UCB PHARMA S.A.; BUeRLI, Roland; HAUGHAN, Alan, Findlay; MACK, Stephen, Robert; PERRY, Benjamin, Garfield; RAPHY, Gilles; SAVILLE-STONES, Elizabeth, Anne; WO2010/52448; (2010); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9

After adding 6-bromoquinoxaline (3.8 g, 18.2 mmol), n-butyl vinyl ether (12.3 mL, 95.2 mmol), potassium carbonate (3.1 g, 22.8 mmol), 1,3-bis(diphenylphosphino)propane (504 mg, 1.3 mmol) and palladium(II) acetate (124 mg, 0.5 mmol) to N,N-dimethylformamide (47 mL) and water (6 mL), the result was stirred and refluxed for 6 hours. After terminating the reaction, the result was cooled to room temperature, 2 N hydrochloric acid was added thereto, and the result was stirred for 0.5 hours. Ethyl acetate was added thereto, the organic layer was washed with water and sodium bicarbonate, dried using anhydrous magnesium sulfate, and filtered. The filtrate was concentrated and purified using column chromatography to obtain a target compound (2.4 g). 1H NMR spectrum (300 MHz, DMSO-d6) delta 10.05(d, 1H), 9.73(t, 1H), 8.71(s, 1H), 7.97(d, 1H), 3.16(s, 3H).

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; Hanmi Pharmaceutical Co., Ltd.; LEE, Kyung Ik; JUNG, Young Hee; SONG, Ji Young; JUN, Seung Ah; (89 pag.)EP3480193; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

To a solution of 11i (30 mg, 110 mumol), 6-bromoquinoxaline (41.8 mg, 200 mumol), Bu4NOAc (78.3 mg, 260 mumol) and Pd(OAc)2 (4.4 mg, 19.6 mol) in NMP (0.5 mL ). The reaction mixture was stirred for 13 h at 100 oC and cooled to room temperature. The mixture was concentrated under reduced pressure, diluted with water, and extracted with EtOAc (3 ¡Á 5 mL). The EtOAc solution was washed with brine (5 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (1:1 hexane/EtOAc) to afford the compound 12i (8.4 mg, 19%) as a yellow solid. TLC: Rf 0.29 (1:1 hexane/EtOAc). mp: 164166 oC. 1H-NMR (400 MHz, CDCl3) delta 8.93 (d, 1H, J = 2.0 Hz), 8.88 (d, 1H, J = 2.0 Hz), 8.18 (d, 1H, J = 8.8 Hz), 8.08 (d, 1H, J = 2.0 Hz), 7.77 (dd, 1H, J = 8.8 Hz, J = 2.0 Hz), 7.74 (t, 1H, J = 8.0 Hz), 7.65 (d, 1H, J = 8.0 Hz), 7.15-7.10 (m, 3H), 6.73 (tt, 1H, JHF = 8.8 Hz, JHH = 2.4 Hz), 2.17 (s, 3H). 13C-NMR (100 MHz, CDCl3) delta 163.3 (dd, JCF = 246.9 Hz, JCF = 13.1 Hz), 158.4, 148.9, 146.3, 146.0, 144.0, 143.2, 142.8, 139.3, 133.6, 133.2, 132.3, 131.7, 130.3, 130.0, 124.0, 115.6, 110.5 (dd, JCF = 19.3 Hz, JCF = 7.6 Hz), 103.9 (t, JCF = 24.9 Hz), 23.8. HRMS (ESI) calcd. for C22H15F2N6 (M+H): 401.1321; found 401.1327., 50998-17-9

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Article; Li, Fei; Park, Yunjeong; Hah, Jung-Mi; Ryu, Jae-Sang; Bioorganic and Medicinal Chemistry Letters; vol. 23; 4; (2013); p. 1083 – 1086;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider